Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) shares traded down 7.1% on Wednesday . The stock traded as low as $1.77 and last traded at $1.83. 51,247 shares were traded during mid-day trading, an increase of 551% from the average session volume of 7,871 shares. The stock had previously closed at $1.97.
Cyclerion Therapeutics Stock Down 7.1 %
The business’s fifty day simple moving average is $2.74 and its 200 day simple moving average is $2.80.
Cyclerion Therapeutics Company Profile
Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.
Read More
- Five stocks we like better than Cyclerion Therapeutics
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Rocket Lab is the Right Stock for the Right Time
- Investing in the High PE Growth Stocks
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- 3 Monster Growth Stocks to Buy Now
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
